Seòmar agus comataidhean

Phase Two of the Women’s Health Plan was published on 20 January 2026.

As part of the next steps for the delivery of Phase Two, a Monitoring and Evaluation Framework is being developed. Part of the work of the Framework will be to set out timelines for the delivery of the 40 actions within Phase Two of the Plan including the national survey on women and girls’ health.

The development of this plan is in the very early stages; therefore, there has not yet been a decision around publication or timescales.

We continue to focus on reducing long waits for all patients including those awaiting gynaecology appointments and treatment, while a longer-term plan is developed.

We have already allocated over £10.5 million additional funding to Health Boards to target long waits for gynaecology this year. The further £2.4 million I announced, alongside the publication of Phase 2 of the Women’s Health Plan, brings the total investment to almost £13 million, demonstrating our commitment to improving care and ensuring women and girls receive a timely diagnosis and access to the support they need.

The latest data shows our plan is working, with waits of more than a year down 18.1% for new outpatients and down 3.9% for inpatient and day-case procedures between July and November 2025.

The Scottish Government unequivocally condemns the abuse experienced by children and young people at the Ladyfield psychiatric unit for children. We offer our full and unreserved apology and recognise the courage of survivors in coming forward to share their experiences. Ladyfield was examined during Phase 9 of the Scottish Child Abuse Inquiry’s public hearings, and the Inquiry’s findings are awaited. The Scottish Government continues to fully participate in the Inquiry process.

The Scottish Government is not aware of any negative price differentials between the purchase costs of gluten-free food products and the NHS reimbursement rate. The Scottish Drug Tariff contains information regarding the prescribing, dispensing and reimbursement of medicines and appliances. Gluten-free food products are reimbursed in line with this process.

The Scottish Government is committed to ensuring that people living with long term conditions such as coeliac disease receive the care and support they need. People who have been diagnosed with coeliac disease or dermatitis herpetiformis can receive a range of gluten-free foods on prescription at no charge. There is a monthly unit allowance and people may choose to use all or part of that allowance to access these gluten-free items on prescription through their local community pharmacy. Health Boards set out the gluten-free food products available on prescription, taking account of local needs and demands, in their prescribing formularies.

The Scottish Drug Tariff contains information regarding the prescribing, dispensing and reimbursement of medicines and appliances. It lists the reimbursement prices paid by the NHS for approved prescribable items. Gluten-free food products are reimbursed in line with this process. Any price updates are imported directly from the UK Dictionary of Medicines and Devices price files by Public Health Scotland, who supply this monthly to PSD to support accurate reimbursement.

The Scottish Government is continuing discussions internally and with NHS perinatal mental health professionals around how counselling and other psychological services (including those provided by third sector organisations) could be expanded and improved to provide appropriate support for those impacted, where they don’t require more specialised NHS support.

There are no plans at this time to publish the map of services which will be used to inform policy.

The supply of medicines, including managing shortages, is a reserved matter and is the responsibility of the UK Government’s Department of Health and Social Care (DHSC). The Scottish Government works closely with the UK Government on all related medicines supply issues and there are well-established and robust processes in place to communicate, address and mitigate any risks as result of any medicines supply issues that occur.

On 2 December, a National Patient Safety Alert was issued about the supply issues affecting epidural bags. The alert outlines actions to minimise the potential impact of the shortage. The DHSC has also sourced sufficient supplies of clinically equivalent alternatives. In Scotland, NHS National Procurement has confirmed that the situation is stable from a supply perspective and Health Boards are receiving allocations of alternative epidural bags, meaning that patients should see no change in their care.

Responsibility for providing education and discussing treatment options lies with clinicians, who are expected to ensure that individuals receive clear, accurate information about all available diabetes technologies when considering their care. Decisions on prescribing specific devices are made by the prescribing clinician in line with clinical guidance and in discussion with the individual.

The Scottish Government supports this through a range of initiatives designed to improve access to reliable information and education. We fund digital resources such as My Diabetes My Way, Scotland’s interactive self-management platform, which provides secure access to personal health records, test results, treatment plans and NHS-accredited eLearning resources. We also invest in DigiBete, a digital tool offering age-appropriate education and practical support for people living with diabetes.

Education is central to the National Closed Loop System Onboarding Programme, hosted by NHS Golden Jubilee. This team provides virtual training and support from experienced clinicians and peer support workers, enabling people anywhere in Scotland to start using diabetes technologies without delay and with confidence.

We work closely with the third sector, including Diabetes Scotland, to promote peer support and community-based education. These partnerships help ensure that people living with diabetes have access to practical advice and lived experience alongside clinical guidance.

Finally, through the Scottish Diabetes Group and its subgroups, we continue to deliver the commitments set out in the Diabetes Improvement Plan (2021–2026). This includes work to improve knowledge and confidence in primary care teams, ensuring that clinicians across Scotland are equipped to discuss technology options effectively with their patients.

We are committed to ensuring that everyone living with diabetes can access clinically appropriate, safe, effective and person-centred care. We know that waiting times for access to diabetes technologies, such as Closed Loop Systems (CLS), remain a challenge, and we are taking action to improve this.

Since 2016, the Scottish Government has invested over £50 million to support technology access, including:

• £29.6 million between 2016-2022 for diabetes technologies
• £8.8 million in 2024-25 to expand CLS access
• £14.6 million in 2025-26 to onboard 2,500 additional individuals and cover recurring consumables

These measures increase capacity and reduce delays by enabling virtual onboarding and freeing up local clinic resources. In addition, the National Onboarding Team, hosted by NHS Golden Jubilee, provides virtual education and training, enabling people anywhere in Scotland to start using diabetes technologies without delay. This innovative model supported almost 1,000 people last year with a 100% satisfaction rate.

The National CLS Onboarding Programme has enabled more than 4,200 people to receive CLS since May 2024. As of September 2025, 77% of under-18s with Type 1 diabetes have access to CLS, and every child or young person should have received at least a referral. This paediatric focus helps prevent complications early and reduce future backlogs.

This builds on Scotland’s strong progress in diabetes technology adoption. According to the 2024 Diabetes Survey, insulin pump use has risen to 23.2% of all people with Type 1 diabetes, up from just 6.3% in 2013. Continuous Glucose Monitoring (CGM) adoption has increased to 85.7% in 2024, compared to 82.5% in 2023, reflecting Scotland’s commitment in digital diabetes care.

We will continue to work with boards to reduce variation and waiting times through targeted funding and performance-based delivery models that prioritise equitable access for all.

The Scottish Government does not hold this information